Shares of Bristol-Myers Squibb Co (NYSE:BMY) have been assigned an average rating of “Hold” from the twenty-two ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $60.46.
BMY has been the subject of several research reports. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Morgan Stanley set a $54.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Thursday, December 20th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. Edward Jones cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. Finally, Credit Suisse Group set a $59.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, February 4th.
BMY stock traded down $0.46 during mid-day trading on Tuesday, reaching $49.64. 618,993 shares of the stock traded hands, compared to its average volume of 19,951,602. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40. Bristol-Myers Squibb has a 52 week low of $44.30 and a 52 week high of $70.05. The stock has a market capitalization of $81.97 billion, a price-to-earnings ratio of 12.48, a price-to-earnings-growth ratio of 1.60 and a beta of 0.83.
The firm also recently declared a quarterly dividend, which was paid on Friday, February 1st. Investors of record on Friday, January 4th were given a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.30%. The ex-dividend date was Thursday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.
Large investors have recently bought and sold shares of the stock. Riverview Trust Co acquired a new position in Bristol-Myers Squibb in the fourth quarter worth about $33,000. Portfolio Solutions LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter worth about $37,000. Gantzert Investment Co. LLC ADV acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $39,000. 1 North Wealth Services LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $42,000. Finally, Larson Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $64,000. 73.19% of the stock is owned by hedge funds and other institutional investors.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Story: Return On Assets
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.